SNY

SNY

• CEO:
• Employees:
• Sector:
• Industry:

SNY News

Latest news about the SNY

• 
  Sanofi's Top-Selling Drug Just Snagged Another Approval From the FDA

  Mega-blockbuster Dupixent was just given the FDA's green light to treat patients with a chronic, progressive inflammatory disease.

  by The Motley Fool at 6/25/22, 12:00 AMView More →
• 
  Why Sanofi May Be a Frontrunner in Endemic COVID-19

  There is a promising outlook for its next generation of vaccines.

  by The Motley Fool at 6/25/22, 12:00 AMView More →
• 
  Sanofi, GSK variant-specific COVID shot found effective against Omicron

  Late-stage data on an experimental COVID-19 vaccine from Sanofi and GSK has showed the shot confers protection against the Omicron variant of the virus, the companies said on Friday.

  by Reuters at 6/24/22, 8:51 AMView More →
• 
  BRIEF-GSK Says Sanofi-GSK First To Report Successful Efficacy Study Against Omicron With COVID Beta-Containing Vaccine

  * GSK - SANOFI-GSK FIRST TO REPORT A SUCCESSFUL EFFICACY STUDY AGAINST OMICRON WITH COVID-19 BETA-CONTAINING VACCINE Further company coverage:

  by Reuters at 6/24/22, 6:54 AMView More →
• 
  Sanofi says next-gen COVID booster shot has potential against main variants

  French drugmaker Sanofi said on Monday an upgraded version of the COVID-19 vaccine candidate it is developing with GSK showed potential in two trials to protect against the virus's main variants of concern, including the Omicron BA.1 and BA.2 strains, when used as a booster...

  by Reuters at 6/13/22, 8:09 AMView More →
• 
  Sanofi's Dupixent gets U.S. approval to treat eczema in young children

  The U.S. Food and Drug Administration approved the use of Sanofi and Regeneron Pharmaceuticals Inc's anti-inflammation drug Dupixent to treat eczema in young children, the two companies said on Tuesday.

  by Reuters at 6/7/22, 9:41 PMView More →
• 
  3 Unstoppable Stocks That Are Higher Than Before the Market Correction

  Market downturns don't affect stocks equally.

  by The Motley Fool at 5/27/22, 12:00 AMView More →
• 
  This Safe Stock Is Dirt Cheap -- and It's Beating the Market

  There's a lot to like about this big pharma juggernaut.

  by The Motley Fool at 5/20/22, 12:00 AMView More →
• 
  KDMN Stock: 6 Things to Know About Biopharma Kadmon Holdings as Shares Skyrocket

  Kadmon Holdings (KDMN) stock is rising higher on Wednesday following news of a deal with Sanofi (SNY) that comes to $1.9 billion.

  by Investor Place at 9/8/21, 12:00 AMView More →
• 
  3 Best Biotech Stocks To Buy for Upcoming Catalysts

  The next few months are critical for these biotech stocks which could witness a massive increase in their stock prices this year

  by Investor Place at 8/12/21, 12:00 AMView More →